

**Alliance for Clinical Trials in Oncology**  
***Multiple Myeloma Committee***

Saturday, May 10  
2:00-5:00pm CDT

**Location**

Intercontinental Chicago O'Hare  
Room Avedon C

**Dial-in Information**

Dial-in: 800-501-8979  
Passcode: 0739814

---

**I. Introductions and Report from Chairman's Meeting**

- a. Funding Reductions from the NCI and Implications

*Paul Richardson, MD; Dana-Farber Cancer Institute*

- b. New SCRC Format, Meeting Schedule, Travel Support, and Administrative Changes

*Scott E Smith MD, PhD, FACP, Executive Officer – Hematology*

*Jim Omel, MD*

**II. Alliance Studies (Completed and Ongoing)**

- a. CALGB 100104 and derived studies in ND MM

*Philip L. McCarthy, MD; Roswell Park Cancer Institute*

*Sarah Holsten, MD PhD, Roswell Park Cancer Institute*

- i. A151210: Understanding the molecular basis for myeloid cell transformation in the plasma cell dyscrasias (*Kelvin Lee MD PhD and Scott Abrams PhD*)

- ii. A151211: Second malignancies in myeloma (*Ola Landgren MD PhD and Alliance group*)

- iii. Update of PFS and OS of 100104 (*SH, PLM, Kouros Owzar, PhD and the Duke statistical center*)

- b. IFM/DFCI 2009 Study in ND MM (BMT CTN 1304); the Determination trial

- i. Study Update; Accrual, Site Activations, Safety Reports, Protocol Amendments

*Paul Richardson, MD; Dana-Farber Cancer Institute*

*Andrea Zeytoonjian; Dana-Farber Cancer Institute*

- ii. Hevylite assay vs standard assays for disease measurement

*Hani Hassoun, MD; Memorial Sloan-Kettering Center*

- c. A061202: Pom/Dex +/- MLN9708 in RR MM

*Peter M. Voorhees, MD; University of North Carolina*

### III. Alliance Studies (Activation Pending)

- a. A061304: Ibrutinib + Rd in relapsed/refractory MM  
*Jacob Laubach, MD; Dana-Farber Cancer Institute*  
*Yvonne Efebera, MD; Ohio State University Medical Center*
- b. A061402: Plasmacytoma  
*Anuj Mahindra, MD; University of California, San Francisco*

### IV. Endorsed Studies

- a. ECOG – E1A11: Rvd vs CRd in ND MM  
*Edward Faber Jr., MD; University of Nebraska Medical Center*
- b. SWOG – S1211: RVD +/- Elo for newly diagnosed high risk MM  
*Todd M. Zimmerman, MD; University of Chicago*
- c. SWOG – S1304: Carfilzomib in RR MM  
*Peter M. Voorhees, MD; University of North Carolina*
- d. ECOG – E3A06: Smoldering myeloma study (lenalidomide vs placebo)  
*Anuj Mahindra, MD; University of California, San Francisco*

### V. Treatment Concepts (Updates and New Proposals)

- a. Novel treatment options (including SCT) at first relapse of MM in transplant naive patients  
*Hani Hassoun, MD; Memorial Sloan-Kettering Center*
- b. RESCUE trial in relapsed MM patients post SCT  
*Todd M. Zimmerman, MD; University of Chicago*  
*Sergio Giralt, MD; Memorial Sloan-Kettering Center*
- c. RIC allo followed by MLN9708 maintenance in newly diagnosed MM  
*Cristina Gasparetto, MD; Duke University Medical Center*
- d. Rd +/- Dara in non-SCT eligible newly diagnosed MM patients  
*Jacob Laubach, MD; Dana-Farber Cancer Institute*  
*Peter M. Voorhees, MD; University of North Carolina*
- e. Proposal for Therapeutic Subcommittee in MM Older Adults: Rationale and First Steps  
*Tanya M. Wildes, MD; Washington University School of Medicine*  
*Sascha Tuchman, MD; Duke University Medical Center*

---

**2014 Fall Group Meeting**  
(Open to all Alliance members)  
November 5-8, 2014  
InterContinental Chicago O'Hare

**Next Conference Call**  
Friday, May 23, 2014  
3:00-4:00pm CST / 4:00-5:00pm EDT